Join the Oncology Voice Network. Join for Free
What is Your Value?: Defining and Driving MSL Value Demonstration
MSLs value demonstration patient-centricity internal collaboration tools and technology for MSLs strategies for undervalued MSLs

What is Your Value?: Defining and Driving MSL Value Demonstration


Share This Article


Summary

In this episode, Tom Caravela welcomes Cherie Hyder to discuss the critical topic of MSLs demonstrating VALUE. The conversation delves into defining value and effectively showcasing it to key stakeholders, including KOLs, with an emphasis on patient-centricity. The role of internal collaboration in enhancing value is examined, along with methods for measuring and communicating this value within organizations. They explore how tools and technology can aid MSLs in enhancing their perceived value and address common challenges faced in value demonstration. Strategies for MSLs who feel undervalued are shared, concluding with Cherie's final advice and closing remarks.

Key Points

  • Emphasizing both quantitative and qualitative metrics is essential for MSLs to effectively demonstrate their value within the organization.
  • Maintaining patient-centricity by understanding and communicating patient experiences and needs can significantly enhance the impact of an MSL's work.
  • Continuous self-investment in skills and capabilities is crucial for MSLs to adapt to changes and remain valuable in a rapidly evolving medical landscape.

Click for Source
MSLs value demonstration, patient-centricity, internal collaboration, tools and technology for MSLs, strategies for undervalued MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges
Partner Avatar MSL Talk: Tom Caravela, Stephanie Otis

The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Explore OVN